Scott Juda

Scott Juda, listed as board member, appears in our data through filings on Inmune Bio, Inc. shares, published by SEC (Form 4). In total, 9 filings cover trades dated from 3 June 2019 to 2 July 2026.

Purchases make up the whole of the open-market record (7 purchases, €421k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 1 option exercise.

A typical purchase (the median) is worth €34k. On 3 out of 6 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 7 July 2026, reports an option exercise of €18k in Inmune Bio, Inc. The latest purchase dates back some time: it was published 865 days ago, on 26 June 2024. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.